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ABSTRACT
Introduction: Absence of pulmonary perfusion during
cardiopulmonary bypass (CPB) may be associated with
reduced postoperative oxygenation. Effects of active
pulmonary artery perfusion were explored in patients
with chronic obstructive pulmonary disease (COPD)
undergoing cardiac surgery.
Methods: 90 patients were randomised to receive
pulmonary artery perfusion during CPB with either
oxygenated blood (n=30) or histidine-tryptophan-
ketoglutarate (HTK) solution (n=29) compared with no
pulmonary perfusion (n=31). The coprimary outcomes
were the inverse oxygenation index compared at
21 hours after starting CPB and longitudinally in a
mixed-effects model (MEM). Secondary outcomes were
tracheal intubation time, serious adverse events,
mortality, days alive outside the intensive care unit
(ICU) and outside the hospital.
Results: 21 hours after starting CPB patients receiving
pulmonary artery perfusion with normothermic
oxygenated blood had a higher oxygenation index
compared with no pulmonary perfusion (mean
difference (MD) 0.94; 95% CI 0.05 to 1.83; p=0.04).
The blood group had also a higher oxygenation index
both longitudinally (MEM, p=0.009) and at 21 hours
(MD 0.99; CI 0.29 to 1.69; p=0.007) compared with
the HTK group. The latest result corresponds to a
difference in the arterial partial pressure of oxygen of
23 mm Hg with a median fraction of inspired oxygen of
0.32. Yet the blood or HTK groups did not demonstrate
a longitudinally higher oxygenation index compared
with no pulmonary perfusion (MEM, p=0.57 and 0.17).
Similarly, at 21 hours there was no difference in the
oxygenation index between the HTK group and those
no pulmonary perfusion (MD 0.06; 95% CI −0.73 to
0.86; p=0.87). There were no statistical significant
differences between the groups for the secondary
outcomes.
Discussion: Pulmonary artery perfusion with
normothermic oxygenated blood during
cardiopulmonary bypass appears to improve
postoperative oxygenation in patients with COPD
undergoing cardiac surgery. Pulmonary artery
perfusion with hypothermic HTK solution does not
seem to improve postoperative oxygenation.
Trial registration number: NCT01614951;
Pre-results.
INTRODUCTION
Pulmonary dysfunction is one of the leading
causes of prolonged hospitalisation, morbid-
ity and mortality after cardiopulmonary
bypass (CPB)-dependent cardiac surgery and
varies from only a short need of mechanical
ventilation to fever, productive cough, pul-
monary oedema, respiratory failure and in
the most severe cases adult respiratory dis-
tress syndrome.1–5 The aetiology is multifac-
torial and can be separated into poor
postoperative lung mechanics and abnormal
gas exchange. However, CPB is considered to
be the main contributor to postoperative
KEY MESSAGES
▸ Although the technical refinement of cardiopul-
monary bypass (CPB) has progressively
improved the surgical outcomes of heart dis-
eases, postoperative CPB-induced lung dysfunc-
tion still remains an important contributing
factor to increased morbidity and mortality,
especially for patients with chronic obstructive
pulmonary disease (COPD).
▸ For patients with COPD undergoing cardiac
surgery this trial shows that pulmonary artery
perfusion with normothermic oxygenated blood
during CPB improves postoperative oxygenation.
▸ This trial outlines strengthened evidence for pul-
monary artery perfusion with blood during CPB
with the need for a larger confirmatory trial to
change clinical practice of CPB for patients with
COPD undergoing cardiac surgery.
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pulmonary dysfunction due to (1) contact of blood with
the heart-lung machine’s artiﬁcial surfaces, (2) perfu-
sion of only the systemic circulation and not the pul-
monary circuit with non-physiological laminar ﬂow,
resulting in (3) release of endotoxins from the splanch-
nic area, and after weaning from CPB (4) warm ischae-
mic reperfusion injury of especially the lungs, all leading
to activation of the inﬂammatory response and conse-
quently interstitial pulmonary oedema.6–8
The lungs have a dual blood supply from the pulmon-
ary and bronchial arteries with extensive collateral con-
nections. Blood supply to the lungs during CPB is
limited to ﬂow through the bronchial arteries and an
ischaemic injury occurs as bronchial blood ﬂow is insuf-
ﬁcient to meet the lungs metabolic demands. It has now
been conﬁrmed in several animal models that bronchial
artery blood ﬂow is decreased substantially during CPB,
and although exposure to CPB alone is enough to cause
pulmonary injury, concomitant cessation of pulmonary
artery ﬂow contributes signiﬁcantly to the development
of postoperative pulmonary dysfunction.9–12
The results of animals studies,13–16 small randomised
trials in infants with congenital heart disease17–20 and
inconclusive minor randomised trials and observational
studies in adults21–25 indicates that pulmonary artery per-
fusion with normothermic oxygenated blood preserves
postoperative oxygenation. Further, lung transplantation
experiences has shown that pulmonary artery perfusion
with a hypothermic preservation solution protects the
lungs from warm ischaemic injury during storage and
transplantation.26 We therefore hypothesised that pul-
monary artery perfusion with normothermic oxygenated
blood or uniform hypothermia by pulmonary artery per-
fusion with a hypothermic preservation solution poten-
tially can attenuate the warm ischaemic injury to the
lungs during CPB.
The aim of our trial was therefore to investigate two
different concepts of pulmonary artery perfusion during
CPB in a patient population with an increased risk of
lung injury due to chronic obstructive pulmonary
disease (COPD).27 We wanted to test two hypotheses:
(1) pulmonary artery perfusion with normothermic oxy-
genated blood and (2) cooling of the lungs by pulmonary
artery perfusion with hypothermic histidine-tryptophan-
ketoglutarate (HTK) solution improves postoperative
oxygenation in patients with COPD undergoing car-
diac surgery compared with (3) no pulmonary artery
perfusion.
METHODS
The Pulmonary Protection Trial was approved by the
Committees on Biomedical Research Ethics of The
Capital Region of Denmark, the Danish Medicines
Agency and the Danish Data Protection Agency and
registered at ClinicalTrials.gov (6 June 2012,
NCT01614951, Principal Investigator Daniel A
Steinbrüchel). Written informed consent was obtained
from each patient prior to randomisation and the trial
was conducted in accord with the ethical standards of
the Helsinki Declarations of 1975.28
The rationale for and design of the trial including the
detailed statistical analysis plan have been published.27 29
The methodology is summarised in the following para-
graph and adheres to Equator guidelines.
Trial design
The Pulmonary Protection Trial was a randomised, paral-
lel group, participants, statistician and conclusion
drawers blinded trial. The good clinical practice unit at
Copenhagen University Hospital monitored adherence
to the protocol and data registration. The steering group
vouches for the accuracy, completeness and statistical
analysis of the data, and for the adherence of this report
to the trial protocol and statistical analysis plan.27 29
Patients
We screened patients 18 years of age or older with
COPD admitted to the Department of Cardiothoracic
Surgery, Rigshospitalet, Denmark for coronary artery
bypass grafting, aortic valve replacement or the two pro-
cedures combined. COPD was diagnosed in patients
with an irreversible airway obstruction (forced expiratory
volume in 1 s (FEV1/forced vital capacity <0.7) and clas-
siﬁed (mild, moderate, severe and very severe) in
accordance with GOLD.30 The main exclusion criteria
were previous heart or lung surgery, previous thoracic
radiation, left ventricular ejection fraction <20%, tra-
cheal intubation or medically treated pneumonia imme-
diately prior to surgery.
Randomisation
Patients were assigned in a 1:1:1 ratio to one of three
interventions (1) pulmonary artery perfusion with nor-
mothermic oxygenated blood, (2) pulmonary artery per-
fusion with hypothermic HTK solution or (3) no
pulmonary artery perfusion during CPB. Randomisation
was performed centrally, on a website hosted by The
Copenhagen Trial Unit, by a computer-generated alloca-
tion sequence in permuted blocks of varying size strati-
ﬁed according to the preoperative lung function in (1)
mild COPD or (2) moderate to very severe COPD.
Blinding
Those blinded to the intervention assignment were: phy-
sicians performing the lung function tests, personnel at
the intensive care unit (ICU) and ward, personnel per-
forming the 90 days follow-up and the statistician and
conclusion drawers. During writing of six abstracts (due
to two coprimary outcomes and three comparisons), the
intervention groups were identiﬁed as 1, 2 and 3 and
abstracts were approved by all authors before the ran-
domisation code was broken.31 Only the operation team
was aware of the intervention assignment due to the
inherent problem with blinding the surgical perfusion
procedure.
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Data collection and verification
Data for the primary outcome and some of the second-
ary outcomes were obtained from direct observations
and measurements during the hospital stay. Data for the
remaining secondary outcomes were obtained at the
90-day follow-up by an in-hospital visit. The primary
outcome and serious adverse events (SAE) were veriﬁed
source data in all patients. Prerandomisation character-
istics and secondary outcomes were veriﬁed by a random
sample of at least 10% of the patients. All data were
registered in case record forms by the trial or clinical
personnel under the supervision of the trial investiga-
tors. The trial database was established by double-
blinded data entry from the case record forms and sub-
sequently merging of the two databases to minimise
typos and errors from converting handwritten data to an
electronic database.
Anaesthesia, surgery and protocol interventions
Anaesthesia was induced using fentanyl (10 µg/kg), pro-
pofol (1–2 mg/kg) and cisatracurium (0.1 mg/kg) and
maintained with sevoﬂurane 0.5–3% and continuous
infusion of remifentanil (15–30 µg/kg/hour). Venous
access was obtained using two peripheral veins. A sheath
for the pulmonary artery catheter and a central line
were inserted in one of the internal jugular veins. The
ventilation mode was preferentially volume controlled
and after CPB positive end expiratory pressure (PEEP)
was set to 5 mm Hg and lung recruitment performed.
Ventilation was ceased during sternotomy and during
CPB, irrespective of trial randomisation.
After heparinisation (350 IU/kg, ACT >480 s), nor-
mothermic CPB (36.5–37.0°C bladder temperature) was
initiated. In the ascending aorta an angled arterial
cannula was placed (DLP 24 FR, Medtronic, Minnesota,
USA) and, the right atrial appendage was provided with
a two-stage venous cannula (36/46 FR, Medtronic,
Minnesota, USA). A membrane oxygenator (Capiox
RX25, Terumo, Tokyo, Japan) and a roller pump
(Stockert S5, Sorin Group, Milano, Italy) were used for
perfusion with laminar ﬂow. The arterial line included a
40 µm ﬁlter (AL06, Pall, New York, USA). Pump ﬂow
was 2.4 L/min/m2 body surface area and mean arterial
pressure was kept between 40 and 70 mm Hg by adminis-
tration of a vasoconstrictor or dilator as appropriate.
For patients in group I and II surgery time was pro-
longed by no more than 10 min.
In group I (normothermic oxygenated blood): the
main pulmonary artery was provided with a straight
arterial cannula (14 FR DLP, Medtronic, Minnesota,
USA), the aorta was cross-clamped, cardioplegia admi-
nistered and non-pulsatile continuous pulmonary perfu-
sion was initiated at 300–400 mL/min. CPB total ﬂow
was calculated by DuBois formula (body surface area
[m2] = Weight [kg]0.425 × height (cm)0.725 × 0.007184)
and 10% was added for the pulmonary perfusion resem-
bling normal physiological conditions. The pulmonary
circuit included extra separate roller-pump in the heart-
circuit and lung-circuit from where the pulmonary
artery perfusion with blood was administered. The tube
from the extra roller-pump was connected to a 12/14 F
straight arterial cannula placed in the pulmonary artery.
The pulmonary artery mean pressure was monitored
continuously via a pressure system attached to the side
branch of the pulmonary cannula. We aimed to main-
tain a pulmonary artery ﬂow with a maximum pulmon-
ary artery mean pressure of 20 mm Hg resembling the
upper limit for normal pulmonary artery pressure. The
blood returning from the pulmonary circuit was drained
to the venous reservoir via a left atrial vent (VT-53218,
CalMed Laboratories, California, USA) inserted through
one of the pulmonary veins. Before aortic cross-clamp
release, the pulmonary artery perfusion was terminated,
the cannula removed and the purse-string suture tied to
seal the insertion puncture.
In group II (hypothermic HTK solution): the pulmon-
ary artery was cannulated as described for group I and
2 L of Custodiol HTK solution at 4°C (Dr Franz Köhler
Chemie GmbH, Bensheim, Germany) were adminis-
tered within 8–10 min without pausing the surgical pro-
cedure. The pulmonary artery mean pressure was
monitored as for group I to guide the infusion rate. The
blood and HTK solution returning from the pulmonary
circuit (average 1800 mL) was directly sucked out from a
small hole in the left atrium, ﬁltered by a cell saver, the
HTK solution was discarded and the puriﬁed red blood
cells (average 100 mL) returned to the patient via the
venous reservoir of the heart–lung machine.
In group III: standard CPB was performed as
described above without pulmonary artery perfusion.
The intubation time was deﬁned from end surgery to
extubation at the ICU. The patients were extubated
when the following criteria were met:
▸ The patient is awake and alert, pain-free, haemo-
dynamically stable with sufﬁcient cough reﬂexes and
swallowing movements.
▸ Pressure support ventilation with support ≤8 cm H2O;
▸ Fraction of inspired oxygen (FiO2 ≤0,40);
▸ Peripheral capillary saturation ≥0.94%;
▸ pH ≥7.34;
▸ PEEP ≤5 cm H2O;
▸ Ventilation rate 10–12/min;
▸ Bleeding from chest drains ≤200 mL/time;
▸ Bladder temperature ≥36°C.
Outcomes
The two primary analyses were comparing the two pul-
monary perfusion groups with no pulmonary perfusion.
Second, a comparison of the two pulmonary perfusion
groups was performed. The two coprimary outcomes
were the inverse oxygenation index (partial pressure of
oxygen (PaO2) divided by FiO2 times mean airway pres-
sure) at a single time point 21 hours after start of CPB,
and longitudinally at ﬁxed time points 1, 3, 5, 7 and
21 hours. Reasons for choosing that time points were
that (1) haemodynamically stable and extubated patients
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are routinely discharged from the ICU at 21 hours after
the start of CPB and (2) the ﬁxed time points (1, 3, 5, 7
and 21 hours) approximately correspond to the follow-
ing surgical events: weaning form CPB, end of surgery, 4
and 6 hours after CPB weaning and 24 hours after anaes-
thetia induction.
For some of the last oxygenation index measurements
the patients were extubated breathing atmospheric air
or receiving oxygen supply through a nasal catheter or
an oxygen mask. In these cases, the oxygenation index
was calculated by ﬁrst converting the external oxygen
supply to an estimated FiO2,
32 and second by setting the
mean airway pressure to 1, removing that parameter
from the equation. For intubated patients respirator set-
tings for FiO2 and mean airway pressure were manually
read and noted at the time when blood was drawn from
the radial artery and blood gas analysis performed to
obtain the PaO2.
The secondary outcomes were: (1) oral tracheal intub-
ation time (hours) after surgery, (2) days alive outside
the ICU, (3) days alive outside the hospital, (4) 30-day
and 90-day mortality and (5) patients with one or more
of the selected SAEs: pneumothorax or pleural effusion
requiring drainage, major bleeding, reoperation, severe
infection, cerebral event, hyperkalaemia, acute myocar-
dial infarction, cardiac arrhythmia, renal replacement
therapy and readmission to the hospital with a
respiratory-related condition.
Statistical analysis
We estimated that a sample size of 3×30 patients was
needed to detect a difference in the PF (PaO2/FiO2)
ratio of 55 mm Hg for the group perfused with oxyge-
nated blood compared with no pulmonary perfusion
with a power of 90% and a two-sided maximal risk of
type 1 error of 0.025.27 29 The PF ratio was used for the
power calculation as no clinical trials in adults had the
oxygenation index as an outcome measure. The oxygen-
ation index includes lung compliance in the equation, a
clinically important parameter for intubated patient’s
oxygenation, and therefore we chose it as our primary
outcome instead of the PF ratio.
The primary analysis included a modiﬁed
intention-to-treat population deﬁned as all randomised
patients, except patients not receiving CPB-dependent
cardiac surgery, and a per-protocol population excluding
patients with major protocol violations deﬁned as: (1)
patients who were randomised to an intervention but
did not receive any intervention and (2) patients who
received an incorrect intervention. For the coprimary
outcomes all analyses were adjusted for the stratiﬁcation
variable (mild COPD or moderate to very severe COPD)
and the patients’ baseline oxygenation index. We then
adjusted for both the stratiﬁcation and design variables
(age, FEV1, left ventricular ejection fraction and the
patients’ baseline oxygenation index).29
Linear regression was used to compare the three
groups’ oxygenation indices at the last time point
21 hours after CPB start. Linear mixed-effects model
(MEM) analysis was used to analyse differences in the
longitudinal measurements of the oxygenation indices
between the three groups.
Proportions of patients with one or more SAEs and
30 days and 90 days mortality were analysed as dichotom-
ous variables using logistic regression adjusted for the
stratiﬁcation variable. The remaining secondary out-
comes were count data analysed with the van Elteren
test33 and were therefore only adjusted for the stratiﬁca-
tion variable.
We will assess the validity of the trial results according
to a ﬁve-point procedure which includes adjustments of
thresholds for signiﬁcance according to the number of
primary outcome comparisons. We will use a p value
threshold for signiﬁcance of 0.025 (0.05/2 because two
primary outcome comparisons are used) and a Bayes
factor threshold for signiﬁcance of 0.1.34
RESULTS
Patients
A total of 3688 patients were screened and 387 patients
meet the inclusion criteria. Ninety patients were rando-
mised due to trial limitations of only two patients per
week. Thirty patients were randomised to pulmonary
artery perfusion with normothermic oxygenated blood,
29 to pulmonary artery perfusion with hypothermic
HTK solution and 31 to no pulmonary artery perfusion.
Eighty-nine of the patients received the intervention and
were included in the intention-to-treat analysis of the
primary outcome and 86 patients were included in the
per-protocol analysis. The 90-day follow-up for survival
was complete for 89 patients (ﬁgure 1 and see online
supplementary table S1).
The baseline characteristics of the patients, comorbid-
ities, preoperative pulmonary status and surgical data are
summarised in table 1. Mean age was 70 years, and 75%
were men. We found no statistically signiﬁcant differences
for the baseline characteristics between the three groups.
Outcomes
Our primary comparisons were (1) pulmonary artery
perfusion with normothermic oxygenated blood com-
pared with no pulmonary perfusion and (2) pulmonary
artery perfusion with hypothermic HTK solution com-
pared with no pulmonary perfusion. For the oxygen-
ation index we present results for both the last
measurement at 21 hours and the longitudinal measure-
ments. The inverse unadjusted mean oxygenation
indices are illustrated in ﬁgure 2 and listed in table 2
which also includes the unadjusted mean PF ratios (not
inversed oxygenation indices see online supplementary
table S2).
For the PF ratio the two perfused groups demonstrates
their lowest PF ratio 1 hour after CPB start with the HTK
group showing the most pronounced deterioration of all
three groups. For the group receiving no pulmonary
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perfusion the lowest PF ratio was found 3 hours after
CPB start. Point estimates for this group demonstrate
the greatest overall change in PF ratio from baseline to
21 hours of 122 mm Hg, compared to only 61 and
84 mm Hg for the groups receiving oxygenated blood
and HTK solution, respectively.
At 21 hours after CPB start, patients who received pul-
monary artery perfusion with oxygenated blood had a
higher oxygenation index compared to patients receiv-
ing no pulmonary artery perfusion during CPB (mean
difference (MD) 0.94; 95% CI 0.05 to 1.83; p=0.04).
This corresponds to a difference in the PaO2 of
22 mm Hg with a median FiO2 of 0.32. The oxygenation
index was also signiﬁcantly higher at 21 hours (MD 0.99;
CI 0.29 to 1.69; p=0.007) and longitudinally ((MEM,
p=0.009) for patients who received pulmonary artery per-
fusion with oxygenated blood compared to pulmonary
artery perfusion with HTK solution. This corresponds to
a difference in the PaO2 of 23 mm Hg with a median
FiO2 of 0.32 (see online supplementary table S3).
We found no statistically signiﬁcant differences in the
longitudinal measurements of the oxygenation index
between patients who received pulmonary artery perfu-
sion with oxygenated blood or HTK solution compared
with no pulmonary perfusion (MEM, p=0.57 and p=0.17,
respectively). The same applied at 21 hours for the
patients who received pulmonary artery perfusion with
HTK solution compared with no pulmonary perfusion
(MD 0.06; 95% CI −0.73 to 0.86; p=0.87). The secondary
and per-protocol analyses did not noticeably change the
results of the coprimary outcome (see online supple-
mentary table S4).
We found no statistically signiﬁcant differences
between the groups for any of the secondary outcomes
(table 3 and see online supplementary table S5)
although point estimates (except for SAEs), favoured
Figure 1 CONSORT flow diagram.
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pulmonary artery perfusion with oxygenated blood com-
pared with no pulmonary perfusion.
The proportions of patients with one or more of the
selected SAEs did not differ between the three groups.
The number of patients with 0–6 SAEs are listed in
online supplementary table S6 and described in details
in online supplementary table S7, both in the online
supplementary appendix. There were no serious adverse
reactions or suspected unexpected serious adverse reac-
tions for any of the trial patients.
Within the total observation time from randomisation
of the ﬁrst patient and until 90 days after randomisation
of the last patient (90–574 days) 8 (9%) patients had
died with an equal distribution in the three groups (3 in
the blood group, 3 in HTK group and 2 in the no pul-
monary perfusion group). The relative high mortality
probably reﬂects that the trial population is elderly and
with a high prevalence of comorbidities.
DISCUSSION
In this randomised clinical trial we tested in a clinical
setting (1) pulmonary artery perfusion with normother-
mic oxygenated blood or (2) cooling of the lungs by
pulmonary artery perfusion with hypothermic HTK solu-
tion compared with (3) no pulmonary artery perfusion
Table 1 Characteristics of the patients at baseline and surgical data*
Characteristics
Oxygenated
blood
(N=29)
HTK solution
(N=29)
No pulmonary
perfusion
(N=31)
Demographic characteristics
Age—year 69.9±10.8 69.6±8.0 70.5±8.9
Male sex—number (%) 22 (75.9) 20 (69.0) 25 (80.6)
Comorbidities—number/total number (%) (number of patients with missing values)
Self-reported COPD 15/29 (51.7) 18/29 (62.1) 19/31 (61.3)
Pulmonary hypertension determined by preoperative
echocardiographic
3/29 (10.3) (5) 7/29 (24.1) (3) 6/31 (19.4) (8)
Arterial hypertension 23/29 (79.3) 24/29 (82.8) 22/31 (71.0)
Chronic atrial fibrillation or flutter 4/29 (13.8) 3/29 (10,3) [1] 5/31 (16.1)
Chronic heart failure † 13/29 (44.8) 6/29 (20.7) [2] 9/31 (29.0)
ASA class IV or worse 1/29 (3.4) 4/29 (13.8) [2] 4/31 (12.9) [2]
Median left ventricular ejection fraction (IQR) 52.5 (41.2–60.0) [1] 50.0 (37.5–60.0) 55.0 (45.0–60.0)
Recent AMI‡ 7/29 (24.1) 11/29 (37.9) 7/31 (22.6)
Insulin-dependent diabetes mellitus 3/29 (10.3) 3/29 (10.3) 2/31 (6.5)
Median estimated creatinine clearance (IQR) § 82.5 (64.2–121.9) 82.7 (62.8–107.3) 86.1 (65.2–106.8)
Previous transit ischaemic attack or stroke 1/29 (3.4) 7/29 (24.1) 7/31 (22.6)
Previous percutaneous coronary intervention 11/29 (37.9) 7/29 (24.1) 7/31 (22.6)
Implantable cardioverter defibrillator or pacemaker 2/29 (6.9) [2] 1/29 (3.4) [1] 1/31 (3.2) [1]
Greater alcohol consumption¶ 11/29 (37.9) 7/29 (24.1) 7/31 (22.6)
Median tobacco pack years (IQR) 40.0 (18.5–51.0) 45.0 (32.5–50.0) 35.0 (20.0–45.0)
Pulmonary function
Median per cent predicted forced
expiratory volume in 1 s. (IQR)
75.0 (56.5–87.5) 79.0 (58.5–88.0) 74.0 (58.0–88.0)
GOLD classification Mild 14/29 (48.3) 14/29 (48.3) 12/31 (38.7)
GOLD classification Moderate 11/29 (37.9) 14/29 (48.3) 17/29 (54.8)
GOLD classification Severe 3/29 (10.3) 1/29 (3.4) 2/31 (6.5)
GOLD classification Very severe 1/29 (3.5) 0/29 (0.0) 0/29 (0.0)
Surgical data
Elective surgery 18/29 (62.1) 16/29 (55.2) 23/31 (74.2)
Urgent surgery 11/29 (37.9) 13/29 (44.8) 8/31 (25.8)
Type of surgery
AVR 7/29 (24.1) 7/29 (24.1) 12/31 (38.7)
CABG 15/29 (51.7) 17/29 (58.6) 17/31 (54.8)
CABG and AVR 7/29 (24.1) 5/29 (17.2) 2/31 (6.5)
Cardiopulmonary bypass time (min) 102.2±53.7 100.9±26.5 98.45±44.6
Aortic cross-clamp time (min) 58.8±37.9 64.3±18.3 61.9±34.7
*Plus–minus values are means±SD. There were no statistical significant differences between the three groups for any of the variables.
†Chronic heart failure was defined as New York Heart Association Class III or worse.
‡Recent AMI is within 3 months prior to the surgery.
§Estimated creatinine clearance by Cockcroft-Gault equation in mL/min/1.73 m2.
¶Greater alcohol consumption was defined as >14 for women and >21 for men units’ alcohol per week.
AMI, acute myocardial infarction; ASA, American Society of Anesthesiologists; AVR, aortic valve replacement; CABG, coronary artery bypass graft;
COPD, chronic obstructive pulmonary disease; GOLD, global initiative for chronic obstructive lung disease; HTK, histidine-tryptophan-ketoglutarate.
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during CPB in cardiac surgery patients with COPD. At
21 hours after starting CPB, patients perfused with oxy-
genated blood had a signiﬁcantly higher oxygenation
index compared with those receiving no pulmonary per-
fusion. However, the p value was above our predeﬁned
signiﬁcance level (0.025) based on multiple compari-
sons.34 The oxygenated blood group had also a signiﬁ-
cantly higher oxygenation index on both the
longitudinal measurements and at 21 hours compared
with the HTK group. The trial was not powered to
detect clinically relevant differences and therefore we
found no signiﬁcant differences between the three
groups in regards to tracheal intubation time, SAEs,
mortality or days alive outside the ICU and outside the
hospital.
As reported in animal studies,13–16 small randomised
trials and observational studies in infants18 19 and
adults,22–25 we have now evaluated and conﬁrmed in a
clinical setting with adult patients with COPD, that pul-
monary artery perfusion with oxygenated blood during
CPB results in a higher postoperative oxygenation. This
was obtained without an increased incidence of compli-
cations or signiﬁcant prolongation of the surgical pro-
cedure. However, we could not conﬁrm the ﬁndings of a
higher postoperative oxygenation in patients receiving
pulmonary artery perfusion with hypothermic Custodiol
HTK solution.15 17 20 21
The severity of postoperative pulmonary dysfunction is
related to the patients’ preoperative pulmonary function
and reduced lung function is associated with increased
morbidity and mortality.35–37 Patients with reduced lung
function like COPD therefore face a multitude of pro-
blems during and after surgery, as cardiac surgery is
offered to an increasingly elderly and sicker population,
with a signiﬁcant age-related decline in respiratory
reserves.38–40 All patients developed reduced PF-ratio
and had, according to the recent Berlin deﬁnition,41 a
mild degree of ARDS with PF-ratios between 200 and
300 mm Hg in the perioperative 24 hours (table 2). In
Figure 2 Oxygenation indices inverse means for the three
groups from cardiopulmonary bypass start and until 21 hours
after.
Table 2 Unadjusted inverse oxygenation indices and PF ratio*
OI mean (95% CI) PF mean (95% CI)
Baseline
Pulmonary perfusion with oxygenated blood 1.15 (0.78 to 1.52) 0.89 392.35 (348.06 to 436.64)
Pulmonary perfusion with HTK solution (0.74 to 1.04) 350.14 (314.80 to 385.48)
No pulmonary perfusion 0.97 (0.83 to 1.11) 413.43 (371.37 to 455.49)
1 hour after CPB start
Pulmonary perfusion with oxygenated blood 0.60 (0.48 to 0.73) 272.00 (225.90 to 318.09)
Pulmonary perfusion with HTK solution 0.46 (0.32 to 0.59) 199.96 (160.15 to 239.77)
No pulmonary perfusion 0.69 (0.55 to 0.83) 293.02 (245.93 to 340.12)
3 hours after CPB start
Pulmonary perfusion with oxygenated blood 0.41 (0.33 to 0.48) 282.11 (237.46 to 326.76)
Pulmonary perfusion with HTK solution 0.36 (0.30 to 0.42) 249.64 (214.58 to 284.70)
No pulmonary perfusion 0.52 (0.27 to 0.77) 267.84 (216.66 to 319.03)
5 hours after CPB start
Pulmonary perfusion with oxygenated blood 0.65 (0.37 to 0.94) 337.15 (260.56 to 413.74)
Pulmonary perfusion with HTK solution 1.12 (0.55 to 1.69) 262.86 (235.55 to 290.18)
No pulmonary perfusion 1.52 (0.67 to 2.37) 285.84 (238.32 to 333.36)
7 hours after CPB start
Pulmonary perfusion with oxygenated blood 1.99 (1.20 to 2.77) 321.00 (286.47 to 355.54)
Pulmonary perfusion with HTK solution 2.14 (1.46 to 2.82) 274.82 (250.64 to 299.11)
No pulmonary perfusion 1.99 (1.23 to 2.76) 277.43 (239.55 to 315.32)
21 hours after CPB start
Pulmonary perfusion with oxygenated blood 4.48 (3.86 to 5.10) 331.04 (285.54 to 376.54)
Pulmonary perfusion with HTK solution 3.45 (3.06 to 3.84) 266.03 (238.91 to 293.15)
No pulmonary perfusion 3.58 (2.93 to 4.22) 291.37 (254.58 to 328.16)
*Intention-to-treat population.
CPB, cardiopulmonary bypass; HTK, histidine-tryptophan-ketoglutarate; OI, oxygenation index; PF, PaO2/FiO2 ratio in mm Hg.
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this respect, it is interesting that the highest PF-ratio at
baseline was seen in the control group, which was also
the group demonstrating the most pronounced deterior-
ation over the next 21 hours with a delta-difference in
PF-ratio from baseline to 21 hours of 122 mm Hg, com-
pared to only 61 and 84 mm Hg for the groups receiving
oxygenated blood and HTK solution, respectively.
Our trial had a number of strengths. The protocol was
pragmatic so routine practice was maintained, and we
predeﬁned the methodology in a protocol, and a detailed
statistical analysis plan, which minimised the risk of data-
driven analyses and outcome reporting bias.42 Additional
strengths were the authors’ unawareness of the random-
isation groups during the statistical analyses and writing
of six abstracts, which were approved by all authors
before the blinding was unveiled.
The limitations of our trial were mainly that the primary
outcome (oxygenation index) was a surrogate outcome
with unknown long-term clinical relevance for the
patients. We chose the oxygenation index, and not PF
ratio, as it includes the mean airway pressure in the calcu-
lation which can be an important correcting parameter
for oxygenation monitoring in mechanically ventilated
patients with excessive pulmonary dysfunction. Second, we
chose our primary comparison to be pulmonary perfusion
with oxygenated blood or HTK solution compared with
no pulmonary perfusion. Comparing the two pulmonary
perfusion techniques were considered explorative, but
came out with the strongest signiﬁcant result. Third, we
had limited power to detect any differences in the second-
ary outcomes, probably due to a small sample size. We
believe that a larger multicentre randomised trial, includ-
ing patients with both reduced and normal lung function
undergoing cardiac surgery, could provide conclusive
results on the short-term and long-term clinical beneﬁts of
pulmonary artery perfusion with oxygenated blood during
CPB. Based on our results we cannot encourage further
exploration of pulmonary artery perfusion with hypother-
mic Custodiol HTK solution during CPB.
In conclusion we found that pulmonary artery perfu-
sion with normothermic oxygenated blood during CPB
resulted in improved postoperative oxygenation for
patients with COPD undergoing cardiac surgery com-
pared with both no pulmonary perfusion and pulmon-
ary artery perfusion with hypothermic HTK solution.
For those patients receiving hypothermic HTK solution
postoperative oxygenation did not improve.
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